US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof
Patent 11352356 was granted and assigned to Takeda Pharmaceutical Company on June, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 21 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+8 properties)
Infobox
Patent Inventor Names
Alastair Rae0
David Edward Ehmann0
Gerald Wayne Shipps, Jr.0
Jeremy Mark Travins0
John Mark Ellard0
Nikolaos Papaioannou0
Sarah Jocelyn Fink0
Thomas Allen Miller0
Edits on 26 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 25 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113523560
Date of Patent
June 7, 2022
0Patent Application Number
169084970
Date Filed
June 22, 2020
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 9 Jun, 2022
Golden AI
Edits made to:
Infobox (+16 properties)
Article (+175 characters)
US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof
Article
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11352356
Date of patent
June 7, 2022
Patent application number
16908497
Date Filed
June 22, 2020
Patent citations
Patent primary examiner
Find more entities like US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
